8-K: Apyx Medical Gains FDA Clearance for AYON Power Liposuction

Apyx Medical Corporation announced expanded FDA 510(k) clearance for its AYON Body Contouring System to include power liposuction, a move expected to enhance market demand and streamline surgical procedures.

Summary

• Apyx Medical Corporation has received expanded 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AYON Body Contouring System.
• This clearance specifically allows the AYON system to include power liposuction, an advanced fat removal technique using a reciprocating cannula.
• The company believes this addition positions AYON as the gold-standard system in surgical aesthetics.
• A limited commercial launch of the power liposuction function is planned to refine training and customer experience before a wider rollout.
• The AYON system integrates fat removal, closed loop contouring, and Renuvion's tissue contraction capabilities into a single platform.
• The company previously filed for this label expansion in October 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as expanded FDA clearance for a key product feature is a significant regulatory and market access achievement.

Positives

• Expanded FDA 510(k) clearance for the AYON Body Contouring System to include power liposuction.
• The addition of power liposuction is expected to drive greater market demand for the AYON system.
• The integrated platform allows surgeons to perform multiple body contouring modalities, streamlining workflow and improving procedural efficiency.
• The company plans a limited commercial launch to optimize customer experience before scaling adoption.

Risks

• The company is subject to the regulatory environment, including obtaining requisite approvals from the FDA and other governmental bodies.
• Sudden or extreme volatility in commodity prices and availability, including supply chain disruptions.
• Changes in general economic, business, or demographic conditions or trends.
• Changes in and effects of the geopolitical environment.
• Liabilities and costs from pending or threatened litigations, claims, disputes, or investigations.
• Risks described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other SEC filings.

Future Outlook

The company anticipates that the addition of power liposuction capability will drive even greater market demand for the AYON system. A limited commercial launch is planned to refine training and customer experience before scaling commercial adoption.

Management Comments

• "With the addition of our advanced power liposuction function, we believe AYON is the gold-standard system in surgical aesthetics."
• "We look forward to building on this success by kicking off a limited commercial launch of the power liposuction function. This will allow our team to work closely with early adopters to refine training, utilization, and the overall customer experience before scaling commercial adoption for power liposuction."
• "By integrating power liposuction into a single, unified platform, we are enabling surgeons to perform multiple critical body contouring modalities within one systemstreamlining workflow, improving procedural efficiency, and supporting optimal patient outcomes."

Industry Context

StockSavvy.ai notes that Apyx Medical's expanded FDA clearance for its AYON Body Contouring System to include power liposuction aligns with the trend in surgical aesthetics towards integrated, multi-functional platforms that enhance surgeon efficiency and patient outcomes. Competitors in the body contouring market are also focusing on technological advancements to offer comprehensive solutions.

Stakeholder Impact

• Shareholders: Potential for increased market demand and revenue growth for Apyx Medical due to expanded product capabilities.
• Surgeons: Enhanced efficiency and streamlined workflow with a single system capable of multiple body contouring modalities.
• Patients: Potential for improved procedural efficiency and optimal outcomes through advanced body contouring treatments.

Next Steps

• Limited commercial launch of the power liposuction function.
• Refine training, utilization, and customer experience with early adopters.
• Scale commercial adoption for power liposuction.

Key Dates

Recommendation

The expanded FDA clearance is a positive step, but the company's future success hinges on the successful commercial launch and market adoption of the power liposuction feature. Further performance data and market reception will be crucial for a stronger recommendation.

Keywords

Apyx Medical, AYON Body Contouring System, FDA 510(k) clearance, Power Liposuction, Surgical Aesthetics, Body Contouring, Renuvion, Liposuction